Genetics and genomics in medicine
Genetics and genomics in medicine focus on analyzing and using genetic data to diagnose, treat and prevent diseases. The continued study of gene functions and interactions in health and disease informs emerging approaches to personalized medicine and population health management strategies for chronic, rare and novel diseases.
Top Stories
-
Feature
04 Nov 2024
AMPEL develops a blood test for cardiovascular disease
Amrie Grammer, AMPEL's co-founder, president, and chief scientific officer of AMPEL BioSolutions, explains the company's CardioGENE blood test for cardiovascular disease risk. Continue Reading
-
Feature
28 Oct 2024
Addressing gene and cell therapy commercialization challenges
InspiroGene addresses some gene and cell therapy commercialization challenges by offering logistics programs, distribution services, a biologics specialty pharmacy and a patient hub. Continue Reading
-
News
14 Jul 2020
Pfizer Commits $100M to Help Fight Rise of Antimicrobial Resistance
The collaboration between the biopharmaceutical companies intends to bring two to four new antibiotics to patients by 2030 due to the rapid rise of antibiotic-resistant infections. Continue Reading
-
News
13 Jul 2020
HHS, DOD, Novavax Partner to Scale-Up COVID-19 Vaccine Doses
Scaling up COVID-19 vaccine doses builds toward the Trump Administration’s Operation Warp Speed goal to begin delivering 300 million doses of safe and effective vaccine to individuals in 2021. Continue Reading
-
News
08 Jul 2020
Kevzara Fails in Phase 3 COVID-19 Clinical Trial
Although potential COVID-19 drug, Kevzara, showed minor benefits in severely ill individuals, the results were countered by the adverse events found in 80 percent of patients. Continue Reading
-
News
07 Jul 2020
Judge Thwarts Biosimilar Competition For Amgen’s Enbrel
The US Appeals Court upheld the validity of two Amgen patents challenged by Sandoz Inc, which developed a biosimilar to Enbrel. Continue Reading
-
News
06 Jul 2020
Pfizer Reports Positive Results for Potential COVID-19 Vaccine
Pfizer and BioNtech’s clinical trial found that its most promising investigational vaccine candidate could be administered in a dose that was well-tolerated by infected patients. Continue Reading
-
News
03 Jul 2020
Pharmaceutical Companies Hike Drug Prices During COVID-19 Pandemic
Pharmaceutical companies have raised drug costs for household drugs, sedatives, anti-depressants, chronic disease drugs, and promising COVID-19 drugs amidst the pandemic, a new report shows. Continue Reading
-
News
29 Jun 2020
Children’s Robitussin, Dimetapp Recalled Due to Overdose Risk
GSK recalled the medicines after discovering that the dosing cups for both products only contained the 20ml graduation, which poses a risk of accidental overdosing. Continue Reading
-
News
24 Jun 2020
AbbVie, Genmab Team Up for Antibody Therapeutics for Cancer
Together, the companies will maximize the development of promising early-stage antibody therapies to bring potential treatments to cancer patients more quickly and efficiently. Continue Reading
-
News
19 Jun 2020
Trulicity Beats Others in Patient Adherence, Real World Data Shows
Individuals with type 2 diabetes taking Trulicity showed higher and longer adherence and persistence than those taking semaglutide or exenatide, real-world data shows. Continue Reading
-
News
15 Jun 2020
Delayed Generic Drug Entry Cost Medicaid $761M, Study Finds
Medicaid paid millions in excess costs over a 7-year period due to generic drug entry delays largely driven by patient litigation, a new study shows. Continue Reading
-
News
03 Jun 2020
Bristol Myers Squibb Announces Commercial Launch of MS Drug
ZEPOSIA is the first and only sphingosine-1-phosphate (S1P) receptor modulator that provides treatment for patients with no genetic test, said Bristol Myers Squibb. Continue Reading
-
News
29 May 2020
Obtaining Contraceptives from Pharmacists Boosts Continuous Adherence
Pharmacist prescriptions of contraception were associated with a contraceptive supply of more than 6 months dispensed, showing an increased continuous adherence. Continue Reading
-
News
26 May 2020
HHS to Expand US-Based Pharmaceutical Manufacturing for COVID-19
HHS will work with a team of private industry partners to expand pharmaceutical manufacturing in the US and produce essential medicine needed during COVID-19 and other public health emergencies. Continue Reading
-
News
13 May 2020
HHS Reveals Plan for Shipping Remdesivir to Hospitals for COVID-19
An HHS agency has started to ship donated remdesivir, a potential COVID-19 treatment, to a handful of states where state health departments will distribute to hospitals. Continue Reading
-
News
12 May 2020
Researchers Link HSV-1 to Alzheimer’s, Creating Hope for a Cure
Researchers at Tufts University are saying an FDA-approved anti-viral medication may help Alzheimer’s after linking the herpes virus to the debilitating disease. Continue Reading
-
News
11 May 2020
Continuous Buprenorphine Treatment Lowers Prescription Opioid Use
Individuals with continuous buprenorphine treatment saw significantly lower opioid-related hospital services, opioid prescriptions, overdose events, and opioid use. Continue Reading
-
News
08 May 2020
Price for COVID-19 Treatment May Range from $10 to $4K, ICER Says
The alternative pricing models for remdesivir present prices based on two different paradigms, a cost recovery approach and a traditional cost-effective analysis. Continue Reading
-
News
07 May 2020
FDA Authorizes Emergency Use of Remdesivir to Treat COVID-19
The EUA will allow remdesivir to be distributed to COVID-19 patients in hospitals most heavily impacted by the virus in both five-day and ten-day treatment durations, Gilead reported. Continue Reading
-
News
06 May 2020
GSK Gains FDA Approval for its PARP Inhibitor Cancer Treatment
Before the FDA approval, just 20 percent of women with ovarian cancer could be treated with PARP inhibitor as monotherapy in the first-line maintenance setting. Continue Reading
-
News
04 May 2020
Demand for Cardiovascular Drugs Increases as COVID-19 Cases Soar
Premier data shows that demand for cardiovascular drugs to treat related and comorbid conditions has spiked, especially in COVID-19 hotspots. Continue Reading
-
News
04 May 2020
Merck Reports Decrease in Pharmaceutical Revenue Due to COVID-19
Merck lowered its 2020 revenue estimates as the coronavirus outbreak continues to impact its sale of physician-administered products, the company’s latest financial results show. Continue Reading
-
News
30 Apr 2020
66% of Adults Report Prescription Drug Price Increases Since 2017
Most US adults said prescription drug prices have risen either “a little” or “a lot” in the last three years, prompting many to question the administration’s progress with lowering costs. Continue Reading
-
News
28 Apr 2020
Sanofi Scores FDA Approval for Quadrivalent Meningitis Vaccine
The latest innovation in quadrivalent meningococcal vaccination is designed to protect individuals two years of age and older from invasive meningococcal disease. Continue Reading
-
News
28 Apr 2020
Johnson & Johnson Expands Manufacturing of Lead COVID-19 Vaccine
J&J signs agreement with Emergent BioSolutions to further the Company’s goal of ensuring a sufficient global supply of its lead promising COVID-19 vaccine. Continue Reading
-
News
21 Apr 2020
Novartis Donates 130M Doses of Hydroxychloroquine to Combat COVID-19
Novartis will work with stakeholders to find the best distribution of hydroxychloroquine to ensure access for patients most in need during the COVID-19 pandemic. Continue Reading
-
News
20 Apr 2020
PBM Reimbursement Significantly Varies for Generic Drugs
A recent analysis also found that PBM reimbursement for generic drugs does not respond to price hikes, leading to pharmacy challenges. Continue Reading
-
News
15 Apr 2020
Premier Presses FDA, FTC for Biosimilar Marketplace Competition
Changes to the Orphan Drug Act, evergreening, and pay-for-delay arrangements were among Premier’s recommendations for improving biosimilar marketplace competition. Continue Reading
-
News
14 Apr 2020
Manufacturing Costs of Potential COVID-19 Drugs as Low as $1
Chloroquine, remdesivir, and other potential COVID-19 drugs can be manufactured for very low prices, between $1 and $29, a new study finds. Continue Reading
-
News
14 Apr 2020
Early Data Indicates Remdesivir is a Promising COVID-19 Drug
A new study showed that potential COVID-19 drug, remdesivir, improved two-thirds of severe coronavirus cases, but there may be problems with limited study data. Continue Reading
-
News
13 Apr 2020
Recent FDA Approvals to Target Chronic Disease Management
Sevenfact, Celgene’s MS drug Ozanimod, and Somryst are prime examples of recent FDA approvals seeking to improve chronic disease management. Continue Reading
-
News
13 Apr 2020
COVID-19 Spurs Eli Lilly to Drop Insulin Costs to $35 a Month
The pharmaceutical company will cap insulin costs during the COVID-19 crisis for individuals with or without commercial insurance. Continue Reading
-
News
08 Apr 2020
Alynlam, Dicerna Partner on RNAi Therapeutics for Liver Disease
The one-time rivals recently announced a partnership to develop and commercialize RNAi therapeutics for the treatment of alpha-1 liver disease. Continue Reading
-
News
07 Apr 2020
ASHP Demands More Manufacturing of Ventilator Drugs for COVID-19
ASHP recently urged the Trump administration to take action to address shortages of supportive ventilator drugs as the number of confirmed COVID-19 cases continues to rise. Continue Reading
-
News
06 Apr 2020
FDA Orders Removal of Prescription, OTC Ranitidine Drugs
FDA orders manufacturers to remove all prescription and OTC ranitidine drugs after testing confirms that high NDMA levels greatly boost the risk of cancer. Continue Reading
-
News
02 Apr 2020
New Study Finds Significant Cost Savings from Biosimilars Use
The study found that biosimilars could save companies over $1.53 million and expanding the biosimilar market can ensure employers can access to affordable medicines. Continue Reading
-
News
01 Apr 2020
Gilead Expands Access to Potential COVID-19 Treatment, Remdesivir
Gilead expands access and ensures affordability to antiviral remdesivir, a potential COVID-19 treatment previously used to treat diseases such as MERS and SARS. Continue Reading
-
News
30 Mar 2020
Bristol Myers Scores FDA Approval for Celgene’s MS Drug Ozanimod
FDA approved the MS drug ozanimod after initially rejecting the drug prior to the Bristol Myers-Celgene merger, but challenges are not over for release of the drug. Continue Reading
-
News
26 Mar 2020
CVS Caremark Implements Measures to Protect COVID-19 Supply Chain
The pharmacy benefit manager of CVS Health will set limits on the quantity of potential drugs and extend certain previously approved prior authorizations to protect the COVID-19 supply chain. Continue Reading
-
News
26 Mar 2020
Revamping Biosimilar Reviews to Spur Drug Development in Oncology
Researchers explore the role of biosimilar reviews for cancer treatments and recommend ways the reviews can provide more information to spur drug development. Continue Reading
-
News
25 Mar 2020
Suppliers Unable to Meet Orders for Potential COVID-19 Drugs
Demand for two potential COVID-19 drugs increased by 6,842% and 2,196%, respectively, creating significant supply chain challenges, Vizient reports. Continue Reading
-
News
12 Mar 2020
FDA, FTC Warn Companies to Stop Selling Fraudulent COVID-19 Drugs
The FDA and the FTC warned the Jim Bakker Show and six other companies to stop selling fraudulent COVID-19 drugs, which may halt legitimate medical treatment. Continue Reading
-
News
11 Mar 2020
FDA Provides Coronavirus Supply Chain Update
The coronavirus supply chain update assures that, in the face of potential drug shortages, there are alternatives available while the agency continues to mitigate disruptions. Continue Reading
-
News
10 Mar 2020
Prescription Drug Prices Spike Following FDA Approval, Study Finds
An analysis found that prescription drug prices for 4 drugs routinely used by hospitals rose by over 500% following FDA approval. Continue Reading
-
News
09 Mar 2020
Pharma Companies Spent $985M On New Drug Development
Pharma companies spent notably more than expected on drug development over a decade, which boosted the cost of developing one therapeutic drug by $1.7 billion. Continue Reading
-
News
06 Mar 2020
Feds Charge Sandoz for Fixing Generic Drug Prices
Sandoz is the third pharma company to be charged for its role in four antitrust conspiracies which allocated customers, rigged bids and fixed generic drug prices. Continue Reading
-
News
04 Mar 2020
Prescription Drug Costs Increased 3X Over the Past Decade
The net and list price gap of prescription drugs continues to widen year over year as net cost rose significantly over ten years, burdening healthcare payers. Continue Reading
-
News
04 Mar 2020
Policymakers Call Out Express Scripts Over Rising Insulin Prices
The US Finance Committee warns pharmacy benefit manager Express Scripts that it must cooperate with its document requests regarding high insulin prices or face a subpoena. Continue Reading
-
News
03 Mar 2020
ICER: New Migraine Drugs Not as Expensive as Previously Thought
ICER is walking back claims that new migraine drugs from Allergan and Biohaven are too expensive compared to their overall benefits. Continue Reading
-
News
03 Mar 2020
CA Firm Files Wrongful Death Lawsuit Over Opioid Dependence Drug
The lawsuit alleges that Alkermes highly misrepresented opioid dependence drug Vivitrol, which led to a preventable overdose death for a 26-year-old patient. Continue Reading
-
News
02 Mar 2020
Pharma Company Earns $311M for Cannabinoid Medicines
GW Pharmaceuticals saw total revenues of $311.3 million for cannabinoid medicines in 2019 and expects more growth and development around the world in 2020. Continue Reading
-
News
27 Feb 2020
FDA Develops Web-Based Resource to Support Pharmacogenetics
The resource will support pharmacogenetics by validating the associations between certain genetic variants, altered drug metabolism, and therapeutic effects. Continue Reading
-
News
26 Feb 2020
GSK Sells 15 Consumer OTC Products to German Pharma Company STADA
Germany-based Stada acquired 15 well-established consumer health brands from GSK to strengthen its over-the-counter drug business throughout Europe. Continue Reading
-
News
24 Feb 2020
Machine Learning Supports Effective Antibiotic Discovery
Antibiotics are vital in modern medicine and implementation of machine learning by pharma companies will decrease costs and boost antibiotic discovery. Continue Reading
-
News
24 Feb 2020
International Reference Pricing Implementation Challenges
Although international reference pricing has been proposed to lower US spending on prescription drugs, this concept may present challenges, researchers find. Continue Reading
-
News
20 Feb 2020
FDA, Indian Government Stop 500 Illicit Prescription Drug Shipments
The FDA’s first bilateral enforcement operation with the Indian Government stopped nearly 500 shipments of illicit prescription drugs from reaching US consumers. Continue Reading
-
News
19 Feb 2020
Prescription Drug Prices Rose 21% as Utilization Remained Steady
HCCI’s latest report shows that average prescription drug prices increased by 21% from 2014 to 2018 while utilization increased just 4% over the five-year period. Continue Reading
-
News
19 Feb 2020
Pharmaceutical Company Mallinckrodt Sued Over Seizure Drug Cost
A class-action lawsuit was filed against pharmaceutical company Mallinckrodt due to the 97,500 percent increase in drug pricing for a specific seizure medication. Continue Reading
-
News
18 Feb 2020
GoodRx Names Top 20 Most Expensive Prescription Drugs in 2020
In their yearly analysis, GoodRx tracked prescription drug prices in an effort to increase transparency for consumers and found that drug prices continued to creep up in 2020. Continue Reading
-
News
11 Feb 2020
HHS Launches Foundry for American Biotechnology to Spur Innovation
The nation’s first Foundry for American Biotechnology will engage regional experts, offer an idea lab, dry and wet labs and manufacturing space and create a commercialization program. Continue Reading
-
News
10 Feb 2020
Biogen Triumphs Over Patent Challenge of Multiple Sclerosis Drug
The patent challenge of Biogen’s multiple sclerosis drug Tecfidera will stop the launch of Mylan’s cheaper generic alternative, while a similar case regarding HIV drug patents went a different way. Continue Reading
-
News
06 Feb 2020
White House Releases Drug Control Strategy for 2020
The Administration added nine new goals to its national drug control strategy for 2020, including reducing opioid prescription fills nationwide and greater access to evidence-based addiction treatment. Continue Reading
-
News
04 Feb 2020
FDA, FTC Join Forces on Biologics Competition
FDA and FTC signed a joint statement, citing “serious concerns about false or misleading statements and their negative impacts on public health and competition.” Continue Reading
-
News
04 Feb 2020
Opposition to International Pricing Index for Part B Drugs Mounts
The administration’s proposal to calculate the reimbursement rate for Medicare Part B drugs based on the International Pricing Index drew criticism from conservatives. Continue Reading
-
News
21 Jan 2020
USMCA Approval Signals Drug Pricing Changes Ahead
Industry groups argued the new trade deal can serve as a model to combat high drug costs via increased generic and biosimilar competition, following the Senate’s passage. Continue Reading
-
News
14 Jan 2020
GAO Flags Lack of 340B Drug Discount Program Oversight
GAO found weaknesses in the oversight of the 340B Drug Discount Program, leading to discounted drugs to ineligible hospitals. Continue Reading
-
News
10 Jan 2020
USMCA Makes its Way to Full Senate Vote After Lobbying Win
The Senate Finance Committee passed the US-Mexico-Canada Trade Agreement of 2019 on Tuesday, in a 25-3 vote. Continue Reading
-
News
08 Jan 2020
Oncologists Influence Peers in Prescribing Novel Therapies
Oncologists who started using a new cancer therapy early on heavily influenced straggling peers with whom they share a close connection. Continue Reading
-
News
19 Nov 2019
Implications of Value-Based Contracting for Drug Companies
Payers and hospitals are looking to value-based contracting with drug companies to reduce prescription drug spending and improve outcomes. Continue Reading
-
News
15 Nov 2019
Role of Pharmacy Benefit Managers in the Pharmaceutical Supply Chain
Pharmacy benefit managers play a central role in determining the cost of medications to consumers. Continue Reading
-
News
15 Nov 2019
Pharmaceutical Marketing Strategies Targeting Medication Adherence
Targeted pharmaceutical marketing strategies can improve medication adherence by making access easier. Continue Reading